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ABSTRACT 39 
 40 
Gene delivery to the primate central nervous system via recombinant adeno-associated 41 
viral vectors (AAV) allows neurophysiologists to control and observe neural activity precisely. A 42 
current limitation of this approach is variability in vector transduction efficiency. Low levels of 43 
transduction can foil experimental manipulations, prompting vector readministration. The ability 44 
to make multiple vector injections into the same animal, even in cases where successful vector 45 
transduction has already been achieved, is also desirable. However, vector readministration has 46 
consequences for humoral immunity and gene delivery that depend on vector dosage and route 47 
of administration in complex ways. As part of optogenetic experiments in rhesus monkeys, we 48 
analyzed blood sera collected before and after AAV injections into the brain and quantified 49 
neutralizing antibodies to AAV using an in vitro assay. We found that injections of AAV1 and 50 
AAV9 vectors elevated neutralizing antibody titers consistently. These immune responses were 51 
specific to the serotype injected and were long lasting. These results demonstrate that 52 
optogenetic manipulations in monkeys trigger immune responses to AAV capsids, suggesting 53 
that vector readministration may have a higher likelihood of success by avoiding serotypes 54 
injected previously. 55 
 56 
57 
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 58 
NEW & NOTEWORTHY 59 
 60 
AAV vector-mediated gene delivery is a valuable tool for neurophysiology, but variability 61 
in transduction efficacy remains a bottleneck for experimental success. Repeated vector 62 
injections can help overcome this limitation but affect humoral immune state and transgene 63 
expression in ways that are poorly understood. We show that AAV vector injections into the 64 
primate CNS trigger long-lasting and serotype-specific immune responses, raising the possibility 65 
that switching serotypes may promote successful vector readministration. 66 
 67 
68 
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INTRODUCTION  69 
 70 
 Genetic techniques for manipulating and monitoring signals in the primate central nervous 71 
system (CNS) require delivering engineered constructs to the brain, conventionally by viral 72 
vector injections. Viral vectors based on adeno-associated virus (AAV) are particularly useful for 73 
these applications because they transduce non-dividing cells and are minimally pathogenic 74 
(Monahan and Samulski, 2000; Diester et al., 2011). However, the transduction efficiency of 75 
seemingly identical AAV vector injections into the primate CNS is variable. This variability poses 76 
a significant barrier to progress because most primate studies use few animals, precluding 77 
remediation by averaging across animals. Low levels of transduction become clear only months 78 
after a vector injection has been made and can thwart experimental manipulations in ways that 79 
are difficult to correct. Increasing the reliability of AAV vector-mediated gene delivery is 80 
therefore an important goal for primate neurophysiology. 81 
 82 
 One factor that can influence the success of gene delivery is the immune status of the 83 
injected animal. Some animals harbor neutralizing antibodies (NAbs) in their blood that bind to 84 
AAV vectors and prevent transduction (Calcedo and Wilson, 2013; Klasse, 2014). This blockade 85 
is a major concern for gene therapy; a lack of pre-existing immunity to AAV is a criterion for 86 
enrollment in some clinical trials (Jaski et al., 2009; Nathwani et al., 2011). Experiments in non-87 
human primates show that low titers of NAbs to AAV can block transduction of some tissues 88 
(Hernandez et al., 1999; Jiang et al., 2006; Wang et al., 2011). The CNS is thought to be 89 
relatively protected against the effects of NAbs by the blood-brain barrier (Poduslo et al., 1994; 90 
Asokan et al., 2012; Treleaven et al., 2012; Freskgård and Urich, 2016), but injections into the 91 
brain necessarily compromise this barrier, providing a route by which AAV vectors can interact 92 
with circulating antibodies and other components of the adaptive immune system. These 93 
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interactions may accelerate the production of antibodies against AAV and limit the efficiency of 94 
AAV vector-mediated transduction. 95 
 96 
 Immune responses to AAV vectors have been investigated in the context of gene therapy, 97 
but differences in protocol between gene therapeutic and neurophysiological experiments 98 
complicate direct comparisons. Gene therapy studies typically involve the delivery of high vector 99 
doses via intravascular, intramuscular, or intrathecal routes, which affect the immune system in 100 
ways that differ qualitatively from the delivery of lower doses directly into the brain parenchyma, 101 
as is typical of neurophysiological studies. When gene therapy studies do make injections into 102 
the brain parenchyma, they typically use small openings in the cranium that are subsequently 103 
protected by host tissue, thereby limiting exposure to non-sterile environments. In contrast, 104 
craniotomies made in primate neurophysiological studies can be large, and foreign devices are 105 
inserted through them on a regular basis. These insertions compromise the blood-brain barrier 106 
and induce reactive changes in astrocytes, considerations that are particularly relevant given 107 
that AAV capsids can be detected in the brain weeks after an injection has been made 108 
(Samaranch et al., 2016), and that astrocytes are capable of antigen presentation (Fontana et 109 
al., 1984; Soos et al., 1998). Finally, gene therapy studies focus on AAV serotypes that have 110 
been approved for use in humans (e.g. AAV2) or those that have low prevalence of 111 
seropositivity in human populations (e.g. AAV.rh10) whereas AAV serotypes 1, 5 and 9, in 112 
addition to AAV2, are common in primate neurophysiological studies.  113 
 114 
 To assess humoral immune responses to AAV vector injections into the nonhuman 115 
primate brain, we quantified NAb titers in blood sera collected before and after injections. We 116 
found that injections of AAV1 and 9 into the cerebral and cerebellar cortices raised NAb titers 117 
consistently by at least 3-fold. These immune responses developed as early as 3 days after an 118 
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injection, lasted for at least several months, and were specific to the serotype of AAV injected. 119 
Re-administration of the same serotype continued to elevate NAb titer beyond that obtained 120 
after a single vector injection. Thus, AAV vector injections typical of primate neurophysiological 121 
experiments have robust effects on humoral immune status.122 
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MATERIALS AND METHODS 123 
 124 
[FIGURE 1 HERE] 125 
Experimental subjects 126 
 Blood samples were obtained from three rhesus monkeys (Macaca mulatta): two females 127 
and one male (7–14 kg). Blood draws were performed by Washington National Primate 128 
Research Center veterinary staff as part of routine physical examinations after sedation 129 
(Ketamine 10 mg/kg). Approximately 2–4 ml of blood were drawn into collection tubes 130 
containing a clotting activator and gel for serum separation (BD Vacutainer, SST #367983). 131 
Following gentle agitation and a 30 min incubation period, collection tubes were centrifuged for 132 
12 min at 1200 RCF, and the separated serum was transferred to cryogenic vials and stored at 133 
–20º C. Blood draws were obtained before and after AAV vector injections into the brain (Fig. 134 
1). Animal care conformed to the NIH Guide for the Care and Use of Laboratory Animals and 135 
was approved by the Institutional Animal Care and Use Committee at the University of 136 
Washington. Animals were on a 12 hour light/dark cycle and pair housed whenever possible. 137 
AAV injections were made in the laboratory during the day. This report was prepared in 138 
accordance with ARRIVE guidelines. 139 
 140 
 141 
AAV vector production 142 
 AAV vectors were produced using a conventional three-plasmid transient transfection of 143 
human embryonic kidney cells (HEK 293T) with PolyethyIenimine (25 kDa, Polysciences). Cells 144 
were cultured in Dulbecco’s Modified Eagle Medium containing 10% Fetal Bovine Serum, 1% 145 
Amphotericin B, Penicillin (50U/mL), and Streptomycin (50µg/mL), and incubated at 37° C with 146 
5% CO2. Following 72 hours of incubation, cells were harvested and pelleted by centrifugation. 147 
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Vectors were released from the cells by repeated freeze-thaw cycles, purified by 148 
ultracentrifugation through an Iodixanol gradient, and exchanged into phosphate buffered saline 149 
(PBS). Vector titers ranged from 1011 –1013 genomic copies/ml (Table 1).  150 
 151 
AAV vector injection methods 152 
Vectors were delivered to the brain via a cannula made of fused silica (Polymicro 153 
Technologies; ~150 μm inner diameter and ~360 μm outer diameter) that was connected to a 154 
Hamilton syringe (Hamilton, 100 μl) held in a manual pump (Stoelting with a Starrett 155 
micromanipulator No.262M). The cannula and syringe were filled with silicone fluid 156 
(Octamethyltrisiloxane, Clearco Products) that was mixed with fluorescent leak detection dye 157 
(Dye-Lite, Tracerline) and filter-sterilized by passage through a Mixed Cellulose Esters 158 
membrane (EMD Millipore; Millex-GS 0.22 µm; SLGS033SB). The dyed silicone fluid served two 159 
purposes: (i) to occupy the full extent of the cannula, less the desired vector volume to be 160 
injected, and (ii) to optimize visualization of the meniscus between the vector and silicone fluid 161 
under illumination with blue light during the injection procedure. Marks delineating 1 μl 162 
increments were placed along the cannula to facilitate tracking of the volume injected. The 163 
injection cannula was beveled at the tip to ease entry into the brain and was loaded into a 164 
custom dual-hydraulic Microdrive system (Narishige) alongside a tungsten recording electrode 165 
(FHC or Alpha Omega). The injection cannula and electrode were lowered into the brain through 166 
a common stainless steel guide tube and were independently moveable.  167 
 168 
Before injections, we planned the placement of injection sites by mapping the extent of 169 
gray matter in the brain region of interest using standard extracellular neurophysiological 170 
techniques. Each injection started at the deepest point in a penetration, and vector was 171 
delivered periodically during cannula retraction to fill the hole left by the cannula. We typically 172 
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injected ~1 μl of vector every ~250–500 μm over 3–5 min while monitoring the position of the 173 
meniscus and waiting 3–5 min between injections. After the final vector injection, we waited 10–174 
15 min before fully retracting the injection cannula to avoid the escape of vector along the 175 
injection track.  176 
 177 
Assay for quantitating AAV neutralizing antibodies 178 
 To quantitate NAbs to AAV, we used an in vitro assay in which HEK 293T cells were 179 
treated with an AAV vector carrying the gene for green fluorescent protein (GFP) downstream of 180 
the cytomegalovirus promoter (CMV). Cells were seeded in 48-well plates (~12500 cells/well), 181 
and after 24 hours of incubation at 37°C with 5% CO2, the culture medium was replaced with 182 
new medium either: (i) alone (i.e. ‘no virus’ control), a condition that provided a lower-bound on 183 
the fluorescence signal in the emission band of GFP, (ii) containing AAV–CMV–GFP without 184 
serum (i.e. ‘no serum’ control), a condition that provided an upper-bound on the percentage of 185 
GFP-positive cells, or (iii) containing a mixture of AAV–CMV–GFP and diluted blood serum.  186 
 187 
 Serum from each monkey was heat-inactivated at 56°C for 35 mins to denature 188 
proteases and other heat-labile complement molecules that could affect cell health or inhibit 189 
transduction non-selectively (Bordet and Gengou, 1901; Calcedo et al., 2009). Serial dilutions of 190 
serum in culture medium were prepared in ratios of 1:200, 1:400, 1:800, 1:1600 and 1:3200. To 191 
these diluted sera, we added AAV–CMV–GFP in an amount empirically determined to achieve 192 
GFP expression in ~25–35% of cells in the absence of serum (see Table 2). Three replicates of 193 
each condition were prepared, yielding a total of 21 samples for each serum tested (5 dilutions + 194 
no virus control + no serum control). All samples were incubated at 37° C for 1 hour before 195 
application to cultured cells.  196 
 197 
10
 
 
 
 After 48 hours of additional incubation, cells were prepared for flow cytometry by 198 
detaching them from the culture plate (Trypsin in 0.25% EDTA), and pelleting them by 199 
centrifugation (850 RCF for 6 min at 18º C). The cell pellet was then resuspended in 1X PBS, 200 
and analyzed immediately. 201 
 202 
[FIGURE 2 HERE] 203 
 204 
Quantifying GFP via flow cytometry 205 
 Cells were counted using a BD LSR II flow cytometer (488 nm excitation; 530 nm 206 
emission). A total of 10,000 events were recorded for each sample tested. As per standard flow 207 
cytometry analysis methods, signal pre-processing included two stages of selection: (i) to 208 
exclude cellular debris and large aggregates of cells (Fig. 2A; gray polygon), and (ii) to exclude 209 
doublets of cells (Fig. 2B; gray rectangle).  210 
 211 
We examined the distribution of GFP fluorescence intensity across cells that passed both 212 
gating procedures (Fig. 2C). The ‘no virus’ control condition was used to select a criterion value 213 
of fluorescence intensity above which 1% of cells were classified as GFP-positive (false alarms). 214 
For each of the remaining sample conditions (serum dilutions and ‘no serum’ controls), we 215 
tallied the number of observations that exceeded the mean criterion value across ‘no virus’ 216 
replicates (Fig. 2C; gray line) and divided this count by the total number of observations to 217 
obtain the percentage of GFP-positive cells.  218 
 219 
We fit the data with a descriptive model based on a decaying exponential function: 220 
 221 
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where y is the percentage of GFP-positive cells, x is the reciprocal of blood serum dilution, and 222 
α and β are fitted parameters. α corresponds to the percentage of GFP-positive cells in ‘no 223 
serum’ controls, less the lower bound of 1%. β corresponds to the efficacy with which the serum 224 
blocks AAV transduction. α and β were estimated using an optimization procedure (Matlab, 225 
fminsearch) that minimized the sum of squared differences between the observed and predicted 226 
percentage of GFP-positive cells. The neutralizing antibody titer was defined as the reciprocal of 227 
the serum dilution corresponding to a 50% decrement in the percentage of GFP-positive cells 228 
from its maximal level (α + 1 in equation 1), referred to as D50. Differences in D50 between pre- 229 
and post-injection sera were tested for statistical significance by randomization tests (10,000 230 
resamples) (Edgington and Onghena, 2007). Statistical comparisons were made between 231 
serum samples that were processed on the same day using the same cell plating density and 232 
vector stocks.233 
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 234 
RESULTS 235 
 236 
 To investigate immune responses to AAV vector injections into the primate brain, we 237 
analyzed blood serum samples from three rhesus macaques, drawn before and after injections 238 
(Fig. 1). AAV vectors carrying optogenetic constructs were injected into the primary visual 239 
cortex (V1), frontal eye fields (FEF) and cerebellum (Table 1). We used a standard in vitro 240 
immunological assay to test for the presence of NAbs to AAV in blood serum (Fig. 2; see 241 
Materials and Methods). For sera that do not contain NAbs to AAV, we expect comparable 242 
transduction efficiency across all samples, regardless of serum concentration. For sera that do 243 
contain NAbs to AAV, we expect that these antibodies will recognize and bind the AAV–CMV–244 
GFP vector used in the assay, thereby reducing vector transduction efficacy and manifesting as 245 
an inverse relationship between serum concentration and the percentage of GFP-positive cells. 246 
 247 
[FIGURE 3 HERE] 248 
 249 
Neutralizing antibody titers increase after AAV injections into the brain 250 
 Serum samples collected before vector injections had little effect on transduction 251 
efficiency (Fig. 3; gray). Only one of these samples reduced transduction efficiency by >50%, an 252 
observation we return to shortly. In contrast, serum samples collected after AAV vector 253 
injections contained NAbs, as shown by the steeper, concentration-dependent reduction in the 254 
percentage of GFP-positive cultured cells (Fig. 3; black). Note that the serum sample from 255 
Monkey S listed as “pre-injection” (Fig. 3B, D, F; gray) was collected ~3 years after this monkey 256 
was first injected with AAV1 (see Table 1) as part of an earlier study (Jazayeri et al., 2012). This 257 
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monkey had not been previously injected with any other viral vector, and Monkeys F and P had 258 
not been injected with any viral vector prior to their first blood draw. 259 
 260 
For each serum tested, we quantified NAbs to AAV as the reciprocal of the serum dilution 261 
corresponding to a 50% decrement in transduction efficiency from its maximal level (D50). 262 
Comparisons of D50 values from pre-injection and post-injection sera demonstrate that injections 263 
of AAV vectors into the monkey brain made as part of optogenetic experiments can result in 264 
significant humoral immune responses to AAV (Fig. 3; triangles; also see Table 3). AAV1 and 265 
AAV9 injections raised NAb titers significantly (p<0.01; Table 3), and AAV5 injections raised 266 
titers nearly significantly (p=0.06 for Monkey S and p=0.03 for Monkey F; compare Fig. 3A–E to 267 
F–G). 268 
 269 
[FIGURE 4 HERE] 270 
 271 
Serotype specificity of neutralizing antibodies 272 
 We considered the possibility that the reduction in transduction efficiency, which we 273 
interpret as an elevation of NAb titers to AAV, was caused by non-specific factors in post-274 
injection serum. If this were the case, we would expect that post-injection serum would block 275 
AAV-mediated transduction of cultured cells irrespective of which serotype was used in the 276 
assay. On the other hand, if the reduction in transduction efficiency was caused by antibodies 277 
that recognize specifically the AAV serotype injected into the brain, we expect to observe little or 278 
no blocking of transduction by post-injection serum when using other serotypes in the assay. 279 
 280 
Sera from two of the three monkeys contributed to this experiment; sera from Monkey S 281 
was excluded because we did not have pre- and post-injection samples flanking the injection of 282 
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a single serotype. Serum from Monkey P, who was injected with AAV9, was tested for NAbs to 283 
AAV1 and AAV5 (Fig. 4A–B). Serum from Monkey F, who was injected with AAV1, was tested 284 
for NAbs to AAV5 and AAV9 (Fig. 4C–D). In none of these cases, did we find measurable 285 
differences in the transduction efficiency of vector that was incubated with pre- and post-286 
injection serum (all D50 <1:200; p>0.1), indicating that the factor in the serum that blocked 287 
transduction was specific to the serotype of AAV that had been injected into the brain.  288 
 289 
[FIGURE 5 HERE] 290 
 291 
As an additional test of serotype specificity, we measured NAbs titers to AAV2, a 292 
serotype we did not inject into any of the monkeys. Sera collected from Monkey P and Monkey 293 
F did not block transduction by AAV2 pre- or post-injection (Fig. 5A, C; all D50 <1:200; p>0.1). 294 
These data further attest to the serotype-specificity of the humoral immune responses. 295 
 296 
 We did observe one case of apparent cross-reactivity between serotypes. Monkey S was 297 
injected with AAV1 into the brain ~3 years before collection of the first serum sample, and this 298 
sample blocked transduction by AAV2 (Fig. 5B, gray) and by AAV1 (Fig 3D, gray). Following 299 
additional injections of AAV1, AAV5, and AAV9 into Monkey S, the NAb titer to AAV2 increased 300 
from a D50 of 1:527±17 to >1:3200 (Fig. 5B, black; p<0.01), suggesting that antibodies produced 301 
in response to AAV1 may have cross-reacted with AAV2. 302 
 303 
[FIGURE 6 HERE] 304 
 305 
Time course of anti-AAV immune responses 306 
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 Monkey F received five AAV1 injections over the course of four months (Table 1). To 307 
measure the effects of these repeated injections on immune status, we analyzed sera collected 308 
at various time points spanning vector injection dates and compared D50 values. Pre-injection 309 
serum did not block transduction by AAV1 (Fig. 6; black; D50 <1:200) whereas serum collected 310 
after each injection (triangles) did (D50 1:3000 ± 30 and >1:3200). Differences in the D50 values 311 
among the first three serum samples were significant (p<0.01; comparing the first sample 312 
collected to the second sample collected, then the second to the third, etc.). Differences in the 313 
D50 values for the last two sera were not significant (p=0.66) because these sera had such high 314 
NAbs titers that even serum diluted at 1:3200 was sufficient to block transduction by > 50%. 315 
These data demonstrate that repeated exposure to an AAV serotype can elevate AAV NAb 316 
titers beyond those obtained after a single injection. 317 
 318 
To investigate the duration of the NAb titer elevation without repeated injections, we 319 
tested sera from the other two monkeys at several time points after a single vector injection. For 320 
Monkey S, we tested serum collected prior to an injection of AAV9, as well as sera collected 23, 321 
34 and 71 days after the injection (Fig. 6; dark gray). Pre-injection serum did not block 322 
transduction by AAV9 (D50 <1:200) whereas the first post-injection serum sample showed 323 
moderate blocking (D50 1:753 ± 35). Sera collected 34 and 71 days post-injection showed 324 
progressively weaker blocking (D50 1:518 ± 12 to 1:221 ± 18). For Monkey P, we tested sera 325 
collected prior to an injection of AAV9, as well as 299 and 606 days after that injection was 326 
made (Fig. 6; light gray). Pre-injection serum did not block transduction by AAV9 (D50 <1:200) 327 
whereas the first post-injection serum showed moderate blocking (D50 1:589 ± 9), and serum 328 
collected 606 days after the injection showed weaker blocking (D50 1:386 ± 15). For both 329 
monkeys, differences between each pair of sequential D50 values were significant (p<0.01). 330 
These data demonstrate that humoral immune responses to AAV injections can last for many 331 
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months but decrease over time (see also Mastakov et al. 2002, Petry et al. 2008).  332 
333 
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 334 
DISCUSSION 335 
 336 
 Injections of AAV vectors into the brain, made as part of optogenetic experiments in rhesus 337 
macaques, elevated NAbs to AAV (Fig. 3). These immune responses were specific to the AAV 338 
serotype injected (Fig. 4) and were persistent (Fig. 6), in agreement with previous studies 339 
(Blacklow et al., 1968; Jiang et al., 2006; Rivière et al., 2006; Nieto et al., 2012; Zerah et al., 340 
2015). Our single example of non-specific blockade of transduction by AAV2 (Fig. 5B) is also 341 
consistent with another report of cross-reactivity to AAV2 following injections of other serotypes 342 
(Kotterman et al., 2015). A new contribution of our study is the finding that small vector doses 343 
injected into the monkey CNS can produce high NAb titers. This result may be due to the 344 
chronic nature of the craniotomy through which we made injections or to repeated breach of the 345 
blood-brain barrier by electrodes or optical fibers preceding or following vector injections. Below, 346 
we discuss the strengths and limitations of the assay we used and how these affect our 347 
interpretation of the data. We then examine the implications of our results for neurophysiological 348 
studies that employ injections of AAV vectors into the primate brain. 349 
 350 
Assay strengths and limitations 351 
The in vitro assay used in this study is the standard for quantifying NAbs to AAV 352 
(Calcedo and Wilson, 2013), and is well suited for investigating the types of immune responses 353 
that are relevant to primate neurophysiology. In contrast, ELISA-based assays cannot 354 
discriminate neutralizing from non-neutralizing antibodies, and in vivo passive transfer assays 355 
provide NAb titers that correlate less well with transduction efficiency in macaques (Wang et al., 356 
2011). 357 
We quantified NAbs to AAV by estimating the blood serum dilution that produced a 50% 358 
decrement in transduction of cultured cells in the assay (D50) on the basis of a fitted function. 359 
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Previous studies have not used fitted functions to interpolate antibody titers, but we found a 360 
mathematical function that described all of our data well, and the D50 values extracted from 361 
these fits were highly repeatable across replicates. Our use of flow cytometry to count a large 362 
number of cells and the short delay between sample preparation and cell counting may have 363 
contributed to the consistency across replicates and the quality of the fits. 364 
 365 
 Estimates of D50 depend on the percentage of GFP-positive cells in the absence of serum. 366 
This is expected: if each cell were transduced by many AAV particles, a high concentration of 367 
NAbs would be required to reduce transduction efficiency to half of the maximal value. To 368 
ensure that the proportion of GFP-positive cells in the absence of serum was similar across 369 
serotypes, we adjusted the concentration of AAV–CMV–GFP in the assay to compensate for 370 
variations in the tropism of each serotype for HEK 293T cells (Table 3). This adjustment, 371 
however, does not equate assay sensitivity across AAV serotypes (Wang et al., 2011; Calcedo 372 
and Wilson, 2013). For serotypes requiring high vector concentrations, sensitivity is low because 373 
higher antibody concentrations are required to neutralize higher AAV concentrations. We used 374 
more AAV9 than AAV5 in the assay, and this is expected to reduce anti-AAV9 titers relative to 375 
anti-AAV5 titers. Nevertheless, anti-AAV9 titers exceeded anti-AAV5 titers in the sera we tested, 376 
an effect that cannot be explained by the concentrations of vector used in the assay.  377 
 378 
 The anti-AAV5 titers we measured may have been low because the AAV5 vector injected 379 
into the brain had the lowest concentration of the vectors we injected (Table 1) and therefore 380 
may have been insufficient to induce a strong humoral immune response. There is little 381 
evidence that AAV5 is less immunogenic than other serotypes: anti-AAV5 titers increase 382 
following intracerebral (Treleaven et al., 2012) or intranasal (Nieto et al., 2009) administration in 383 
mice, and intramuscular AAV5 injections prevent successful readminstration (Rivière et al., 384 
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2006). The anti-AAV9 titers we measured may have been higher because AAV9 crosses the 385 
blood-brain barrier more readily than AAV5 (Foust et al., 2009; Gray et al., 2011; Samaranch et 386 
al., 2012).  387 
 388 
All of the pre-injection sera we tested were negative for NAbs, except one (Monkey S 389 
tested positive for anti-AAV2 antibodies). Had we tested higher serum concentrations, we might 390 
have measured NAb titers in other pre-injection sera, but even if so, these titers would have 391 
necessarily been lower than the titers we did measure. We tested only serum concentrations 392 
<1:200 for three reasons. First, we were interested in large effects; low NAbs titers are less 393 
likely to be important for the reliability of AAV-mediated transduction of the brain than high titers. 394 
Second, non-specific factors in serum affect transduction efficiency at high concentrations 395 
(Wang et al., 2010; van der Marel et al., 2011). Third, using low concentrations of serum allowed 396 
us to test for NAbs to a greater number of serotypes from each serum sample. 397 
 398 
Implications for neurophysiological studies 399 
We found that injections of AAV1 and AAV9 increased NAb titers consistently. 400 
Readministration of these serotypes had mixed effects on the success of gene delivery in vivo. 401 
In one animal (Monkey F), we successfully transduced multiple brain areas with multiple 402 
injections of a single serotype (AAV1) separated by many weeks. Nevertheless, it remains 403 
possible that the extent of transduction produced by the later injections would have been larger 404 
in an animal naïve to AAV1. In another animal (Monkey S), readministraton of the same 405 
serotype (AAV1) failed to transduce cerebellar cortex after an injection into V1, whereas 406 
injection of a novel serotype (AAV9) into the cerebellar cortex was successful. This result 407 
suggests that switching serotypes may be an effective strategy for increasing the likelihood of 408 
successful readministation of AAV vectors to the primate CNS, consistent with studies 409 
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performed in the primate airway (Nieto et al., 2009), rat striatum (Peden et al., 2004), and 410 
mouse skeletal muscle (Rivière et al., 2006).  411 
 412 
Other strategies to overcome the anti-AAV immune response include 413 
immunosuppression and plasmapheresis (Lorain et al., 2008; Monteilhet et al., 2011; Mingozzi 414 
and High, 2013), but these may have adverse consequences for monkeys prepared for chronic 415 
neurophysiological recordings. Whether such measures are warranted for neurophysiological 416 
studies is unclear. A practical guide to procedures that circumvent anti-AAV immune responses 417 
awaits a better understanding of the relationship between AAV transduction efficiency in vitro 418 
and in vivo. Clarifying this relationship requires experiments with multiple animals, sequential 419 
vector injections, blood draws, and quantitative histological analyses. 420 
 421 
Knowing how high the NAb titer has to be to prevent CNS transduction would be useful 422 
but is challenging. NAb titers measured by different protocols are not directly comparable.   423 
Many additional factors contribute to transduction efficiency (e.g. vector dose, serotype, tissue 424 
target, route of administration, and time between injections), and disentangling the relative 425 
contributions of each factor is a daunting task. For example, pharmacological disruption of the 426 
blood-brain barrier in mice allows even modest NAb titers to block striatal transduction 427 
(Janelidze et al., 2014). Mechanical disruption of the blood-brain barrier, as is typical of 428 
optogenetic experiments in monkeys, may exert a similar effect.  429 
 430 
Effects of pre-existing immunity 431 
Different mammalian species have natural, pre-existing immunity to different AAV 432 
serotypes. For example, monkeys tend to be seropositive for AAV7, AAV8 and AAV.rh10 but not 433 
AAV2, whereas the opposite is true for humans (Gao et al., 2003; Calcedo et al., 2009; Calcedo 434 
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and Wilson, 2013). Pre-existing immunity limits AAV vector-mediated transduction of the liver 435 
and heart (Jiang et al., 2006; Manno et al., 2006; Jaski et al., 2009; Wang et al., 2010; Wang et 436 
al., 2011), but the CNS appears to be minimally affected (Sanftner et al., 2004; Jiang et al., 437 
2006). Whether a lack of pre-existing immunity should be a requirement for including a monkey 438 
in a neurophysiological study is an open question, but our results suggest that it is not critical. 439 
Naturally occurring NAb levels tend to be low (Rapti et al., 2012; Calcedo et al., 2015) and we 440 
were able to readminister AAV1 to Monkey F successfully when this animal’s NAbs titer was 441 
well outside of this range. 442 
 443 
Conclusion 444 
Delivery of optogenetic constructs to the primate CNS via injections of AAV vectors 445 
increased neutralizing antibody titers to AAV capsid. The antibody titers we measured are easily 446 
in the range expected to limit the transduction of non-CNS tissues, but how high titers must be 447 
to block CNS transduction remains unclear. Significant effort has been directed towards 448 
documenting which serotypes of AAV best transduce which structures and cell types. Our 449 
results indicate that the humoral immune status of the animal used for experimentation may be 450 
an additional factor to consider when selecting a viral vector for gene delivery.451 
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 452 
TABLE 1: Details of viral vector injections made into the brain of non-human primates 453 
Monkey Injection date Brain area AAV vector construct Vector titer 
(genomes /ml)
Total 
volume 
(μl) 
P 11/10/2014 V1 rAAV9–hSyn–oChIEF–citrine 1.44 x 1013 16 
P 11/11/2014 V1 rAAV9–hSyn–oChIEF–citrine 1.44 x 1013 16 
S 06/08/2011 V1 rAAV1–hSyn–ChR2–mCherry 5.50 x 1011 12 
S 03/31/2015 Cerebellum rAAV1–L7–ChR2–mCherry 8.45 x 1012 15 
S 04/01/2015 Cerebellum rAAV9– L7–ChR2–mCherry 1.41 x 1013 15 
S 04/03/2015 Cerebellum rAAV5–hSyn–ArchT–eYFP 8.08 x 1011 11 
F 04/22/2015 FEF rAAV1–hSyn–oChIEF–citrine 2.2 x 1012 15 
F 04/24/2015 FEF rAAV1–hSyn–oChIEF–citrine 2.2 x 1012 12 
F 07/22/2015 Cerebellum rAAV9– L7–ChR2–mCherry 1.41 x 1013 17 
F 07/23/2015 Cerebellum rAAV5–hSyn–ArchT–eYFP 8.08 x 1011 17 
F 08/03/2015 Cerebellum rAAV1–L7–ChR2–mCherry 1.53x 1013 17 
F 09/01/2015 Cerebellum rAAV1–L7–eNphR3.0–eYFP 7.00 x 1012 17 
F 09/02/2015 Cerebellum rAAV1–L7– eNphR3.0–eYFP 7.00 x 1012 18 
 454 
 455 
456 
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 457 
TABLE 2: Number of genomic copies of AAV vector used in the assay. 458 
 459 
AAV serotype Vector titer 
(genomes /ml) 
Vector quantity used 
(genomes/sample) 
rAAV1–CMV–GFP 2.50 x 1012 1.97 x 108
rAAV2–CMV–GFP 1.62 x 1012 3.44 x 106
rAAV5–CMV–GFP 4.82 x 1012 2.54 x 109
rAAV9–CMV–GFP 3.61 x 1013 6.27 x 109
 460 
461 
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 462 
TABLE 3: Quantification of anti-AAV antibodies before and after injections into the brain. 463 
 464 
Monkey AAV serotype Pre-injection D50 Post-injection D50 
 
 P value 
P AAV9 < 1:200 1:589 ± 9 P < 0.01 
S AAV9 < 1:200 1:753 ± 35 P < 0.01 
S AAV1 1:423 ± 18* > 1:3200 P < 0.01 
S AAV5 < 1:200 < 1:200 P = 0.06 
F AAV9 < 1:200 1:2034 ± 161 P < 0.01 
F AAV1 < 1:200 1:3000 ± 30 P < 0.01 
F AAV5 < 1:200 < 1:200 P = 0.03 
 465 
 466 
* Note: this animal had received an injection of AAV1 in 2011, ~3 years prior to the collection of 467 
the serum sample tested for NAbs to AAV1. 468 
Standard errors were estimated by bootstrapping (200 resamples). 469 
P values were estimated by randomization tests (10,000 resamples).  470 
471 
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 472 
FIGURE CAPTIONS 473 
 474 
Figure 1. Blood draw and AAV vector injection timeline. Three rhesus monkeys received 475 
AAV vector injections as part of optogenetic experiments (white triangles; also see Table 1). 476 
Blood samples were drawn before and after injections (black triangles), and sera were collected 477 
for testing. Sera contributing to the data shown in Fig. 3–5 are highlighted (black dots). 478 
 479 
Figure 2. Flow cytometry methods. Cells were analyzed by fluorescence activated cell 480 
sorting. A. Cells were gated to exclude cellular debris and large aggregates of cells (gray 481 
polygon). B. Cells were also gated to exclude doublets of cells (gray rectangle). C. Cells that 482 
passed both gating procedures were analyzed for GFP signal; those that achieved a criterion 483 
level of GFP expression (gray line) were classified as GFP-positive. 484 
 485 
Figure 3. Comparing NAbs to AAV before and after vector injections. Sera collected before 486 
and after injections into the brain of three monkeys were analyzed for NAbs to the AAV serotype 487 
that was injected. A–G. Pre-injection sera (gray) tested negative for NAbs to AAV. The only 488 
exception was the pre-injection serum for Monkey S (in D), which was collected ~3 years after 489 
an injection of AAV1. Post-injection sera (black) contained NAbs to AAV. We quantified NAbs in 490 
each serum using the D50 value (triangles, see Materials and Methods). 491 
 492 
Figure 4. Serotype specificity of NAbs. Sera collected before and after injections into the 493 
brain of two monkeys were analyzed for NAbs to AAV serotypes that were not injected. Plotting 494 
conventions are as in Figure 3. 495 
 496 
26
 
 
 
Figure 5. Testing for cross-reactivity of NAbs to AAV2. Sera collected before and after 497 
injections into the brain of three monkeys were analyzed for NAbs to AAV2, a serotype that was 498 
not injected. Plotting conventions are as in Figure 3. 499 
 500 
Figure 6. Time course of AAV immune responses. Sera collected from three monkeys at 501 
different time points relative to a single vector injection, or repeated vector injections (triangles; 502 
only for Monkey F), were analyzed for NAbs to the serotype that was injected.503 
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